Sandbox vidit: Difference between revisions

Revision as of 21:09, 6 February 2014

Stabilization phase (1-2 months):
❑ Transition when patient has:

No withdrawal symptoms
Minimal or no side effects
No uncontrollable craving for opioid agonists
❑ Begin with buprenorphine/naloxone combination, increasing dose by 2/0.5-4/1 mg per week till stabilization is achieved, most stabilizing at 16/4-24/6 mg}
❑ As patient stabilizes, transition to alternate day or every third day regimen by doubling and tripling daily doses respectively

@@ Line 1: / Line 1: @@
 {{familytree/start |summary=PE diagnosis Algorithm.}}
-{{familytree | | | | | | | | | | | | | | F01 | | | | |F01=Stabilization phase (1-2 months): <br> Transition when patient has:
+{{familytree | | | | | | | | | | | | | | F01 | | | | |F01=<div style="float: left; text-align: left">Stabilization phase (1-2 months): <br> ❑ Transition when patient has:
 :* No withdrawal symptoms <br>
 :* Minimal or no side effects <br>
-:* No uncontrollable craving for opioid agonists <br> Begin with buprenorphine/naloxone combination, increasing dose by 2/0.5-4/1 mg per week till stabilization is achieved, most stabilizing at 16/4-24/6 mg} <br> As patient stabilizes, transition to alternate day or every third day regimen by doubling and tripling daily doses respectively}}
+:* No uncontrollable craving for opioid agonists <br> ❑ Begin with buprenorphine/naloxone combination, increasing dose by 2/0.5-4/1 mg per week till stabilization is achieved, most stabilizing at 16/4-24/6 mg} <br> ❑ As patient stabilizes, transition to alternate day or every third day regimen by doubling and tripling daily doses respectively </div>}}
 {{familytree | | | | | | | | | | | | | | | | | | | | | }}
 {{familytree | | | | | | | | | | | | | | | | | | | | | }}